Tecsys (TCS) investor relations material

Executive summary

• Q1 FY2027 delivered record total revenue of $50.0 million, record SaaS bookings, and record Adjusted EBITDA, driven by healthcare expansion and strong Elite SaaS growth.

• Elite SaaS ARR and revenue grew 24% year-over-year, with total SaaS ARR up 18% and SaaS now representing 60% of total revenue.

• Net profit rose 306% year-over-year to $3.1 million ($0.21 per diluted share), with Adjusted EBITDA up 113% to $6.9 million.

• The company raised full-year FY2027 guidance for Elite SaaS revenue, total SaaS revenue, total revenue, and Adjusted EBITDA margin based on robust Q1 performance and pipeline strength.

• Focus remains on expanding within the $3B ARR total addressable market, especially in U.S. health systems and targeted distribution segments.

Financial highlights

• Total revenue in Q1 FY2027 was $50.0 million, up 9% year-over-year.

• SaaS revenue was $22.7 million, up 18% year-over-year; Elite SaaS revenue grew 24% year-over-year.

• Gross profit increased to $26.5 million, representing a 53% gross margin.

• Adjusted EBITDA was $6.9 million, up 113% year-over-year; net profit reached $3.1 million (CAD 0.21 per diluted share).

• SaaS ARR was $93.7 million (+18% year-over-year); Elite SaaS ARR was $89.6 million (+24% year-over-year).

Outlook and guidance

• FY2027 guidance raised: Elite SaaS revenue growth now 21%-23% (up from 18%-20%), total SaaS revenue growth 16%-18% (up from 13%-15%), total revenue growth 11%-14% (up from 5%-8%), and Adjusted EBITDA margin 11%-14% (up from 11%-13%).

• Projected SaaS margin expansion, with Elite SaaS margins running over 75% on latest infrastructure.

• Strong SaaS bookings and pipeline provide confidence in achieving updated targets.

• Continued measured investment expected, including hiring across functions, which may impact margins in coming quarters.

• Positioned to dominate a $3B ARR TAM across health systems and targeted distribution markets.